GPCR/G protein


All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
B6729 NAS-181Summary: rat 5-HT1B receptor antagonist -
B6741 BMY 45778Summary: partial agonist at IP1 prostacyclin receptors -
B6742 N-ArachidonylglycineSummary: Endogenous anandamide-like compound -
B6754 GR 127935 hydrochlorideSummary: 5-HT1B/1D receptor antagonist -
B6758 OleylethanolamideSummary: PPAR-α agonist -
B6765 Rimcazole dihydrochlorideTarget: Sigma ReceptorsSummary: σ receptors antagonist -
B6766 CL 316243 disodium saltSummary: murine-selective β3 adrenoceptor agonist -
B6769 SR 59230A hydrochlorideSummary: A potent, selective β3 adrenoceptor antagonist -
B6773 SDZ 21009Summary: β-adrenoceptor and 5-HT1A/1B receptor antagonist -
B6776 LY 215840Summary: 5-HT2/5-HT7 receptor antagonist

